PixarBio Ribbon Cutting Ceremony With Fort Lee New Jersey Mayor, Mark Sokolich Set For August 9, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation will celebrate the opening of our new office in Fort Lee, N.J. on August 9, 2016 at 11:00AM EST. PixarBio is extending an open invitation to the general public interested in learning more about our morphine strength, but non-addictive pain treatment for the hospital setting, for the battlefield, or acute and chronic pain. For attendee RSVP and media kits please email info@pixarbio.com.

“We’re now established in the pharmaceutical corridor of the world, with labs and offices located between New Hampshire and New Jersey”

Fort Lee, N.J. Mayor Mark Sokolich will attend the ribbon cutting ceremony, to welcome PixarBio to the Fort Lee business community. PixarBio executives, lead scientific team, and investors will be among the guests at the ceremony. Born and raised in Fort Lee, Mayor Sokolich graduated from Rutgers, earned a law degree from Seton Hall University and has been practicing law as managing partner at Sokolich & Macri since 1998. He took office as Mayor of Fort Lee in 2008 and was re-elected in 2011.

NeuroRelease™, a Morphine Strength, non-addictive pain treatment has expected FDA approval in 2018. As we’re moving through the FDA approval process, it’s time to build our commercial teams, led by our Chief Commercial Officer David Kaplan out of Fort Lee, N.J. “We’re now established in the pharmaceutical corridor of the world, with labs and offices located between New Hampshire and New Jersey,” said PixarBio CEO Frank Reynolds

Market analysis confirms significant market demand for a 14-day post-op pain treatment, and its potential to change the practice of medicine, especially with FDA approval expected for 7-day NeuroRelease™ in 2019. PixarBio pain pipeline also includes a 4-8 hour, a three Day and a 90-Day treatment all have expected FDA approvals in 2020. NeuroRelease™ is biodegradable, and non-toxic so NeuroRelease™ is the only non-opiate under review at the FDA that can be re-injected to extend treatment timelines. “NeuroRelease™ represents the holy-grail of pain treatment, and the quality of the KOL’s we signed this summer to our clinical advisory board, speaks volumes to the potential market opportunity and to the clinical impact of NeuroRelease™,” said CEO Frank Reynolds.

Last month PixarBio Corporation was awarded the Boston Business Journal’s “2016 Best Places to Work”. The award recognizes PixarBio as one of the region’s best firms, offering the greatest professional opportunities and work environments to innovate; the company is excited to bring that same workplace environment to our Fort Lee, New Jersey office.

Location of Ribbon Cutting is less than 1 mile from the George Washington Bridge:

2200 Fletcher Avenue
Suite 301
Fort Lee NJ 07024
11:00AM EST
info@pixiarbio.com

About PixarBio Corporation
Cofounded by Frank M. Reynolds, MIT’s Dr. Robert S. Langer, Katrin Holzhaus, Dr. Jason Criscione, Haining Dai, Xi Chen, and Dr. Amer Khalil. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. For more information visit www.pixarbio.com.